SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934 (Amendment No. 8)*

Soleno Therapeutics, Inc. (Name of Issuer)

Common Stock, \$0.001 par value per share (Title of Class of Securities)

> 834203309 (CUSIP Number)

Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

November 14, 2024 (Date of Event Which Requires Filing of this Statement)

	(Dute of Event White Requires Fining of this Statement)
	e filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this edule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
	e: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for a parties to whom copies are to be sent.
*	The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 834203309

1.	Names of Reporting Persons.					
	Perceptive Advisors LLC					
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) □ (b) ⊠					
3.	SEC U	se Or	ıly			
4.	4. Source of Funds (See Instructions)					
	AF					
5.	Check	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)				
6.	Citizer	Citizenship or Place of Organization				
	Delaw					
		7.	Sole Voting Power			
	mber of		0			
Ben	hares eficially	8.	Shared Voting Power			
	vned by Each		1,770,792			
Re	porting	9.	Sole Dispositive Power			
	erson With		0			
		10.	Shared Dispositive Power			
			1,770,792			
11.	Aggreg	gate A	mount Beneficially Owned by Each Reporting Person			
	1,770,792					
12.	2. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)					
13.	3. Percent of Class Represented by Amount in Row (11)					
	4.1%					
14. Type of Reporting Person (See Instructions)						
	00					

CUSIP No. 834203309

1.	1. Names of Reporting Persons.					
	Perceptive Life Sciences Master Fund, Ltd.					
2. Check the Appropriate Box if a Member of a Group (See Instructions)						
	(a) □ (b) ⊠					
3.	SEC U	se Or	ıly			
4.	Source	of Fu	ands (See Instructions)			
WC						
5.	Check	II DIS	sclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)			
6.	Citizer	ship	or Place of Organization			
	Corimo	n Iala	ndo			
	Cayma	7.	Sole Voting Power			
		,.	Sole voling rower			
	mber of		0			
	Shares eficially	8.	Shared Voting Power			
Ov	vned by		1,770,792			
	Each porting	9.	Sole Dispositive Power			
P	erson		0			
With		10.	Shared Dispositive Power			
		10.	Shared Dispositive Fower			
			1,770,792			
11.	Aggreg	gate A	mount Beneficially Owned by Each Reporting Person			
	1,770,7	792				
12.						
13.	13. Percent of Class Represented by Amount in Row (11)					
15.	15. 1 closic of Chass represented by Amount in Row (11)					
	4.1%					
14. Type of Reporting Person (See Instructions)						
	CO					

CUSIP No. 834203309

1.	. Names of Reporting Persons.				
	Joseph Edelman				
2.	2. Check the Appropriate Box if a Member of a Group (See Instructions)				
	(a) □	(1	b) 🗵		
2	OEC II		1		
3.	SEC U	se On			
4.	Source	of Fu	ands (See Instructions)		
5.	AF Charle	:cD:-	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
5.	Спеск	II DIS	closure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)		
6.	Citizer	ship	or Place of Organization		
	United		s of America		
		7.	Sole Voting Power		
Nu	mber of		0		
	hares	8.	Shared Voting Power		
	eficially and by				
	Each		1,770,792		
	porting	9.	Sole Dispositive Power		
Person			0		
	With	10.	Shared Dispositive Power		
			1,770,792		
11.	Aggreg	gate A	mount Beneficially Owned by Each Reporting Person		
	1.770.702				
12.	1,770,792 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)				
12.	. Check if the Aggregate Amount in Now (11) Excludes Certain Shares (See Instructions)				
13.	Percen	t of C	lass Represented by Amount in Row (11)		
	4.107				
14.	4.1% 4. Type of Reporting Person (See Instructions)				
17.	7. Type of Reporting Letson (occ monucuous)				
	IN				

Item 5. Interest in Securities of the Issuer

Item 5 of the Schedule 13D is amended and supplemented as follows:

- (a) The information set forth in rows 11 and 13 of the cover pages to this Amendment No. 8 to Schedule 13D is incorporated by reference and assumes the exercise of pre-funded warrants held by the Reporting Persons to purchase 250,000 shares of the Issuer's Common Stock (the "Pre-Funded Warrants"). The percentage set forth in row 13 is based on 43,117,432 shares of Common Stock outstanding as of October 31, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2024, and assumes the exercise of the Pre-Funded Warrants.
- (b) The information set forth in rows 7 through 10 of the cover pages to this Amendment No. 8 to Schedule 13D is incorporated by reference and assumes the exercise of the Pre-Funded Warrants.
- (c) Except as set forth on <u>Schedule A</u>, as amended and restated with this Amendment No. 8, no Reporting Person has effected any transaction in shares of Common Stock in the past sixty days.
- (e) On November 14, 2024, the Reporting Persons ceased being holders of 5% or more of the outstanding shares of the Issuer's Common Stock.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 19, 2024

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

Schedule A

<u>Fund</u>	Date	Transaction	Number of shares	Price
Perceptive Life Sciences Master Fund, Ltd.	9/23/2024	Sell	16,717	\$48.42
Perceptive Life Sciences Master Fund, Ltd.	9/24/2024	Short Sale	75,000	\$47.27
Perceptive Life Sciences Master Fund, Ltd.	9/25/2024	Short Sale	37,233	\$45.50
Perceptive Life Sciences Master Fund, Ltd.	10/01/2024	Short Sale	44,485	\$49.45
Perceptive Life Sciences Master Fund, Ltd.	10/02/2024	Short Sale	36,315	\$49.98
Perceptive Life Sciences Master Fund, Ltd.	10/03/2024	Short Sale	25,000	\$49.19
Perceptive Life Sciences Master Fund, Ltd.	10/04/2024	Short Sale	50,000	\$49.53
Perceptive Life Sciences Master Fund, Ltd.	10/07/2024	Short Sale	33,446	\$48.12
Perceptive Life Sciences Master Fund, Ltd.	10/08/2024	Short Sale	50,000	\$51.13
Perceptive Life Sciences Master Fund, Ltd.	10/08/2024	Short Sale	50,000	\$56.07
Perceptive Life Sciences Master Fund, Ltd.	10/08/2024	Short Sale	50,000	\$53.13
Perceptive Life Sciences Master Fund, Ltd.	10/08/2024	Short Sale	50,000	\$55.33
Perceptive Life Sciences Master Fund, Ltd.	10/09/2024	Sell (options)	5,000	\$ 3.80
Perceptive Life Sciences Master Fund, Ltd.	10/16/2024	Short Sale	37,493	\$54.53
Perceptive Life Sciences Master Fund, Ltd.	10/17/2024	Short Sale	65,007	\$53.44
Perceptive Life Sciences Master Fund, Ltd.	10/21/2024	Short Sale	9,841	\$53.32
Perceptive Life Sciences Master Fund, Ltd.	10/22/2024	Short Sale	23,689	\$53.96
Perceptive Life Sciences Master Fund, Ltd.	10/23/2024	Short Sale	21,775	\$52.97
Perceptive Life Sciences Master Fund, Ltd.	11/12/2024	Sell	15,867	\$57.21
Perceptive Life Sciences Master Fund, Ltd.	11/13/2024	Sell	25,000	\$56.67
Perceptive Life Sciences Master Fund, Ltd.	11/14/2024	Sell	30,000	\$54.59
Perceptive Life Sciences Master Fund, Ltd.	11/14/2024	Cover Short	1,551,977	N/A
Perceptive Life Sciences Master Fund, Ltd.	11/15/2024	Sell	29,133	\$52.13
Perceptive Life Sciences Master Fund, Ltd.	11/18/2024	Sell	5,000	\$52.07
Perceptive Life Sciences Master Fund, Ltd.	11/18/2024	Sell	10,000	\$51.23
Perceptive Life Sciences Master Fund, Ltd.	11/18/2024	Sell	5,000	\$52.15
Perceptive Life Sciences Master Fund, Ltd.	11/18/2024	Sell	4,783	\$52.21
Perceptive Life Sciences Master Fund, Ltd.	11/19/2024	Sell	7,424	\$51.53